Saudi Press

Saudi Arabia and the world
Thursday, Oct 02, 2025

AstraZeneca and Oxford defend Covid vaccine trials after questions raised in the U.S.

AstraZeneca and Oxford defend Covid vaccine trials after questions raised in the U.S.

“We believe that this product will never be licensed in the U.S.,” one group of critical U.S.-based analysts wrote this week.

AstraZeneca and the University of Oxford are defending the results and methods used in their phase three vaccine trials on the back of criticism from experts in the U.S., stressing the “highest standards” were used and that “additional analysis will be conducted.”

AstraZeneca shares are down by around 6% this week after questions were raised over its vaccine candidate, for which the company said combined results revealed it to be 70% effective. The figure came from combining a smaller group of people who received an unintentionally lower dose of the vaccine — and by what a company spokesperson has called “serendipity” — produced 90% effectiveness, and a larger group who received a higher dosage, showing only 62% effectiveness.

Pascal Soriot, CEO of AstraZeneca, confirmed to Bloomberg on Thursday the British pharmaceutical giant was likely to run an additional global trial to evaluate the efficacy of its Covid-19 vaccine.

Chief of the White House’s Operation Warp Speed, Moncef Slaoui, and others in the U.S. have expressed concern over the age group tested, saying 90% efficacy was only shown for the lowest risk group, which numbered 2,741 people below the age of 55. The group whose results displayed 62% effectiveness numbered 8,895.

AstraZeneca pushed back against the criticism, emphasizing monitoring of the study by the external Data Safety Monitoring Board (DSMB) and the fact that the data released Monday constituted mere interim results and that more data would follow.

“The studies were conducted to the highest standards,” a spokesperson for AstraZeneca told CNBC on Thursday. “An independent DSMB safety monitoring committee oversees the studies to ensure safety and quality. The DSMB determined that the analysis met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine.”

“More data will continue to accumulate and additional analysis will be conducted refining the efficacy reading and establishing the duration of protection,” the spokesperson said.


The University of Oxford, for its part, explained the discrepancy between dosage allotments. It said an initial over-estimation of the dose of the new vaccine batches had resulted “in a half dose of the vaccine being administered as the first dose” due to a “difference in the manufacturing process.”

“The methods for measuring the concentration are now established and we can ensure that all batches of vaccine are now equivalent,” it added.

Harsh criticism


Particularly harsh criticism came from U.S.-based health care and biotech investment bank SVB Leerink, whose analysts wrote Monday: “We believe that this product will never be licensed in the U.S.”

“This belief is based on the design of the company’s pivotal trials which does not appear to match the FDA’s requirements for representation of minorities, severe cases, previously infected individuals and elderly and other increase risk populations,” the analysis said.

In response, a spokesperson at AstraZeneca stressed the results were interim and that more data was to be accumulated and more analysis to be carried out.

Defenders of the trials have pointed out that the criticism seems to come primarily from within the U.S., home of the only other Western vaccine candidates to announce higher effectiveness in their vaccine test results: Pfizer-BioNTech and Moderna, who earlier this month announced their vaccines showed as much as 95% effectiveness.


John LaMattina, a former president of Pfizer Global R&D, tweeted on Tuesday: “Hard to believe that the FDA will issue an EUA for a vaccine whose optimal dose has only been given to 2,300 people. More data for this dosing regiment will be needed.” Slaoui was previously on the board at Moderna and also worked at GlaxoSmithKline.

Cost, distribution, logistics


Outside of the U.S., the Oxford-AstraZeneca vaccine garnered praise, particularly for its relative ease of manufacturing and transport and its low cost compared to potential competitors. The vaccine would sell at between $3 and $5 per dose while those of Pfizer-BioNTech and Moderna would go for $20 per dose and $32 to $37 per dose, respectively.

The Pfizer-BioNTech vaccine candidate, as an mRNA vaccine, also requires extremely cold storage temperatures of negative 94 degrees Fahrenheit and special transport equipment. The Moderna vaccine can be stored for up to six months at minus 4 degrees Fahrenheit.


The Oxford-Astrazeneca results “are very positive results when we recall that the hurdle for a good enough vaccine was set at 50-60%, in line with the flu virus,” Dr. Gillies O’Bryan-Tear, policy chair at the U.K.-based Faculty of Pharmaceutical Medicine, said Monday.

“The great advantage of this Oxford vaccine over the mRNA vaccines is that it can be manufactured easily and transported at ordinary fridge (not freezer) temperatures, so can be transported and stored using the existing vaccine cold chain infrastructure. The group has promised to provide the vaccine not-for-profit to developing nations.”

AstraZeneca has said its vaccine can be stored, transported and handled at normal refrigerated conditions (36-46 degrees Fahrenheit) for at least six months and administered within existing health-care settings. It has also pledged to distribute the vaccine at no profit “for the duration of the pandemic.”

Newsletter

Related Articles

Saudi Press
0:00
0:00
Close
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Trump Organization Teams with Saudi Developer on $1 Billion Trump Plaza in Jeddah
Electronic Arts to Be Taken Private in Historic $55 Billion Buyout
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
Nvidia and Abu Dhabi’s TII Launch First AI-&-Robotics Lab in the Middle East
UK, Canada, and Australia Officially Recognise Palestine in Historic Shift
New Eye Drops Show Promise in Replacing Reading Glasses for Presbyopia
Dubai Property Boom Shows Strain as Flippers Get Buyer’s Remorse
Top AI Researchers Are Heading Back to China as U.S. Struggles to Keep Pace
JWST Data Brings TRAPPIST-1e Closer to Earth-Like Habitability
UAE-US Stargate Project Poised to Make Abu Dhabi a Global AI Powerhouse
Trump and Starmer Clash Over UK Recognition of Palestinian State Amid State Visit
Saudi Arabia cracks down on music ‘lounges’ after conservative backlash
Saudi Arabia Signs ‘Strategic Mutual Defence’ Pact with Pakistan, Marking First Arab State to Gain Indirect Access to Nuclear Strike Capabilities in the Region
Sam Altman sells the 'Wedding Estate' in Hawaii for 49 million dollars
Turkish car manufacturer Togg Enters German Market with 5-Star Electric Sedan and SUV to Challenge European EV Brands
World’s Longest Direct Flight China Eastern to Launch 29-Hour Shanghai–Buenos Aires Direct Flight via Auckland in December
New OpenAI Study Finds Majority of ChatGPT Use Is Personal, Not Professional
Kuwait opens bidding for construction of three cities to ease housing crunch.
This Week in AI: Meta’s Superintelligence Push, xAI’s Ten Billion-Dollar Raise, Genesis AI’s Robotics Ambitions, Microsoft Restructuring, Amazon’s Million-Robot Milestone, and Google’s AlphaGenome Update
Indian Student Engineers Propose “Project REBIRTH” to Protect Aircraft from Crashes Using AI, Airbags and Smart Materials
Could AI Nursing Robots Help Healthcare Staffing Shortages?
Turkish authorities seize leading broadcaster amid fraud and tax investigation
Qatari prime minister says Netanyahu ‘killed any hope’ for Israeli hostages
Apple Introduces Ultra-Thin iPhone Air, Enhanced 17 Series and New Health-Focused Wearables
Big Oil Slashes Jobs and Investments Amid Prolonged Low Crude Prices
Social Media Access Curtailed in Turkey After CHP Calls for Rallies Following Police Blockade of Istanbul Headquarters
Did the Houthis disrupt the internet in the Middle East? Submarine cables cut in the Red Sea
Gold Could Reach Nearly $5,000 if Fed Independence Is Undermined, Goldman Sachs Warns
Uruguay, Colombia and Paraguay Secure Places at 2026 World Cup
Trump Administration Advances Plans to Rebrand Pentagon as Department of War Instead of the Fake Term Department of Defense
Tether Expands into Gold Sector with Profit-Driven Diversification
Trump’s New War – and the ‘Drug Tyrant’ Fearing Invasion: ‘1,200 Missiles Aimed at Us’
At the Parade in China: Laser Weapons, 'Eagle Strike,' and a Missile Capable of 'Striking Anywhere in the World'
Information Warfare in the Age of AI: How Language Models Become Targets and Tools
Israeli Airstrike in Yemen Kills Houthi Prime Minister
After the Shock of Defeat, Iranians Yearn for Change
YouTube Altered Content by Artificial Intelligence – Without Permission
Iran Faces Escalating Water Crisis as Protests Spread
More Than Half a Million Evacuated as Typhoon Kajiki Heads for Vietnam
HSBC Switzerland Ends Relationships with Over 1,000 Clients from Saudi Arabia, Lebanon, Qatar, and Egypt
Sharia Law Made Legally Binding in Austria Despite Warnings Over 'Incompatible' Values
Dogfights in the Skies: Airbus on Track to Overtake Boeing and Claim Aviation Supremacy
Tim Cook Promises an AI Revolution at Apple: "One of the Most Significant Technologies of Our Generation"
Are AI Data Centres the Infrastructure of the Future or the Next Crisis?
Miles Worth Billions: How Airlines Generate Huge Profits
Zelenskyy Returns to White House Flanked by European Allies as Trump Pressures Land-Swap Deal with Putin
Beijing is moving into gold and other assets, diversifying away from the dollar
Cristiano Ronaldo Makes Surprise Stop at New Hong Kong Museum
Zelenskyy to Visit Washington after Trump–Putin Summit Yields No Agreement
×